NASDAQ:KRYS Krystal Biotech (KRYS) Stock Price, News & Analysis $147.70 -3.06 (-2.03%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$149.26 +1.56 (+1.06%) As of 08/29/2025 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Krystal Biotech Stock (NASDAQ:KRYS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Krystal Biotech alerts:Sign Up Key Stats Today's Range$147.56▼$151.1350-Day Range$134.94▼$156.9852-Week Range$122.80▼$207.84Volume257,853 shsAverage Volume409,475 shsMarket Capitalization$4.27 billionP/E Ratio30.02Dividend YieldN/APrice Target$210.38Consensus RatingModerate Buy Company Overview Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. Read More Krystal Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreKRYS MarketRank™: Krystal Biotech scored higher than 95% of companies evaluated by MarketBeat, and ranked 53rd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingKrystal Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageKrystal Biotech has only been the subject of 4 research reports in the past 90 days.Read more about Krystal Biotech's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth64.17% Earnings GrowthEarnings for Krystal Biotech are expected to grow by 64.17% in the coming year, from $6.14 to $10.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is 30.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 270.89.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is 30.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.34.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 4.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Krystal Biotech's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.61% of the float of Krystal Biotech has been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Krystal Biotech has recently increased by 8.28%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.87 Percentage of Shares Shorted13.61% of the float of Krystal Biotech has been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Krystal Biotech has recently increased by 8.28%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.76 News SentimentKrystal Biotech has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Krystal Biotech this week, compared to 8 articles on an average week.Search Interest8 people have searched for KRYS on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,487,943.00 in company stock.Percentage Held by Insiders13.70% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Krystal Biotech's insider trading history. Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRYS Stock News HeadlinesDoes Inhaled KB707’s Progress Signal a New Chapter for Krystal Biotech’s (KRYS) Pipeline Strategy?August 28 at 10:09 PM | sg.finance.yahoo.comHC Wainwright Reiterates "Buy" Rating for Krystal Biotech (NASDAQ:KRYS)August 24, 2025 | americanbankingnews.com“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druckenmiller — just raised nearly $1 billion in funding. Early backers believe it could be one of the most impactful breakthroughs of our lifetime. Whitney Tilson calls it “Helios” — and says a tiny Massachusetts firm sits at the center of what could become a global investment megatrend. If he’s right, this could mark the start of a seismic shift in how the world powers its future.August 30 at 2:00 AM | Stansberry Research (Ad)A Glimpse Into The Expert Outlook On Krystal Biotech Through 10 AnalystsAugust 22, 2025 | benzinga.comKrystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting UpdateAugust 22, 2025 | seekingalpha.comKrystal Biotech price target lowered to $216 from $219 at ChardanAugust 22, 2025 | msn.comKrystal Biotech says prioritizing inhaled KB707, pauses enrollment in OPAL-1August 22, 2025 | msn.comKrystal Biotech adjusts pipeline to prioritize inhaled antitumor agentAugust 22, 2025 | msn.comSee More Headlines KRYS Stock Analysis - Frequently Asked Questions How have KRYS shares performed this year? Krystal Biotech's stock was trading at $156.66 on January 1st, 2025. Since then, KRYS shares have decreased by 5.7% and is now trading at $147.70. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) released its quarterly earnings data on Monday, August, 4th. The company reported $1.29 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. The company earned $96.04 million during the quarter, compared to analysts' expectations of $95.42 million. Krystal Biotech had a trailing twelve-month return on equity of 15.21% and a net margin of 40.85%. Read the conference call transcript. When did Krystal Biotech IPO? Krystal Biotech (KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO. Who are Krystal Biotech's major shareholders? Krystal Biotech's top institutional investors include State Street Corp (4.68%), Soleus Capital Management L.P. (3.19%), Braidwell LP (2.51%) and Redmile Group LLC (2.29%). Insiders that own company stock include Krish S Krishnan, Suma Krishnan, Daniel Janney, Dino A Rossi, Kathryn Romano, Andrew C Orth and Julian S Gangolli. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Krystal Biotech investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings8/04/2025Today8/30/2025Next Earnings (Estimated)11/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRYS CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees210Year Founded2017Price Target and Rating Average Price Target for Krystal Biotech$210.38 High Price Target$245.00 Low Price Target$166.00 Potential Upside/Downside+42.4%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$4.92 Trailing P/E Ratio30.02 Forward P/E Ratio24.06 P/E GrowthN/ANet Income$89.16 million Net Margins40.85% Pretax Margin46.98% Return on Equity15.21% Return on Assets13.81% Debt Debt-to-Equity RatioN/A Current Ratio9.68 Quick Ratio9.33 Sales & Book Value Annual Sales$290.52 million Price / Sales14.71 Cash Flow$4.54 per share Price / Cash Flow32.51 Book Value$35.96 per share Price / Book4.11Miscellaneous Outstanding Shares28,940,000Free Float24,978,000Market Cap$4.27 billion OptionableOptionable Beta0.70 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:KRYS) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.